Printer Friendly

DEPRENYL RESEARCH LIMITED GAINS APPROVAL FOR ELDEPRYL AS FIRST LINE TREATMENT FOR PARKINSON'S DISEASE

DEPRENYL RESEARCH LIMITED GAINS APPROVAL FOR ELDEPRYL AS FIRST LINE
 TREATMENT FOR PARKINSON'S DISEASE
 TORONTO, April 21 /PRNewswire/ -- Deprenyl Research Limited (NASDAQ: DEPLF) today announced receipt of a Notice of Compliance from Canada's Health Protection Branch allowing the drug Eldepryl(R) to be prescribed alone for first line treatment in patients diagnosed with Parkinson's disease.
 Dr. Roger Mailhot, director of Scientific Affairs for Deprenyl, stated, "This is a significant moment not only for our company but in particular for the recently diagnosed Parkinsonian patient. Eldepryl offers a treatment early in the disease process which can delay the onset of symptoms which adversely affect the patient's social or employment life. We continue our efforts to show this benefit is related to a neuro-protective effect of Eldepryl which slows the progression of Parkinson's disease." Prior to this authorization Eldepryl was indicated only for combination use with levodopa in late- stage Parkinson's disease.
 The company stated that this regulatory decision opens a larger market opportunity for Eldepryl. In Parkinson's disease, which affects about 70,000 Canadians, the potential usage of Eldepryl will span an estimated 30,000 patients of whom, up to now, no more than 10,000 patients were being treated with the company's leading drug, Eldepryl. In 1991, Eldepryl sales were Cdn.$13.7 million.
 Dr. Morton P. Schulman, co-chairman of Deprenyl Research Limited, said, "Sales of Eldepryl to early stage Parkinson's patients will begin immediately and should contribute materially to the company's pharmaceutical revenues and earnings."
 Deprenyl Research Limited is an independent Canadian pharmaceutical company which is building a pipeline of products largely devoted to Parkinson's disease, other neurological diseases and disorders of aging.
 -0- 4/21/92
 /CONTACT: Dr. Morton P. Schulman. co-chairman, Dr. Martin Barkin, executive vice president, or Dr. Roger Mailhot, director-scientific affairs, all of Deprenyl Research, 416-537-4372, or fax, 416-537-1653; or Irving L. Straus of Straus Corporate Communications, 212-768-2477, or fax, 212-768-2476, for Deprenyl Research/
 (DEPLF) CO: Deprenyl Research Limited ST: Ontario IN: MTC SU: ERN


CK-TS -- NY024 -- 0473 04/21/92 10:04 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 21, 1992
Words:339
Previous Article:WARNER-LAMBERT ACHIEVES RECORD EARNINGS AND SALES IN FIRST QUARTER
Next Article:CACI ANNOUNCES RESULTS FOR FY92 THIRD QUARTER; EARNINGS UP 43 PERCENT


Related Articles
DEPRENYL RESEARCH CO-CHAIRMAN SENDS LETTER TO SHAREHOLDERS
DEPRENYL ADJOURNS APPLICATION FOR INJUNCTION
DEPRENYL RESEARCH COMMENTS ON NEWSPAPER REPORT
DEPRENYL RESEARCH REPORTS RECORD SALES AND EARNINGS AND EIGHTH CONSECUTIVE INCREASED QUARTERLY DIVIDEND
DEPRENYL RESEARCH LIMITED REPORTS EARNINGS
DEPRENYL RESEARCH SETS THE FACTS STRAIGHT
DEPRENYL RESEARCH SETS THE FACTS STRAIGHT
DEPRENYL RESEARCH REPORTS RECORD EARNINGS, STRONG SALES AND TENTH CONSECUTIVE INCREASED QUARTERLY DIVIDEND
DEPRENYL RESEARCH LIMITED ANNOUNCES ELDEPRYL(R) LISTED ON THE ONTARIO DRUG BENEFIT FORMULARY
INTRODUCTION OF GENERIC PARKINSON DRUG TO HELP PATIENTS AND PROVINCIAL GOVERNMENTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters